UPDATE : Friday, June 5, 2020
HOME Pharma
Ministry recalls 2 drugs with quality problems
  • By Lee Hye-seon
  • Published 2017.03.06 07:30
  • Updated 2017.03.06 15:12
  • comments 0

The Ministry of Food and Drug Safety said Friday that it would recall Belviq tab, an antiobestic drug made by Ildong Pharmaceutical, and some of IV-Globulin SN Inj, Green Cross’ immunoglobulin products, because of quality problems.

Belviq has developed problems in the product’s outer shape while IV-Globulin SN Inj had an alien substance resulting from outside mixing. The ministry

Ministry of Food and Drug Safety

Some of the Belviq tabs with manufacturers’ serial number of “1630F036” have proved faulty. The ministry recalled them after detecting changes in the outlooks of Belviq, which take the shape of blue morsulus, or round tablet, coated with films, classifying its hazard as Grade 3. Drugs categorized as Grade-3 are those which rarely cause ill effects or show no proven ill effects but have problems in color, taste or packaging.

The expiration date of the recalled products is March 31, 2020. Distributors, pharmacies, and medical institutions have only to stop selling the drugs and return them to Ildong, the ministry said.

In the case of IV-Globulin SN Inj, Green Cross recalls its products after a consumer found foreign substance and informed the fact to its manufacturer. The company will recall the drugs with manufacturer serial number of “352A16274” and the entire volume of 50-ml products.

The ministry classified hazard of the drugs that fail to meet the quality standards, by containing excessive contents of main ingredients and other reasons, as Grade 2. Grade-2 drugs are those which cause side effects, which last temporarily or can be cured completely.

Green Cross is visiting stores and manufacturers to recall the products. Pharmacies and medical institutions also have to stop selling and return them, the ministry said.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Hye-seon
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top